Antiangiogenic Gene Therapy Shows Promise in Treating Colon Cancer

Scientists at Yale University have successfully used short interfering RNA (siRNA) to inhibit the expression of vascular endothelial growth factor (VEGF) A in human colon cancer cells, resulting in a significant decrease in cellular proliferation. Researchers hypothesized that VEGF inhibition would impede the growth of colon cancer cells, and their findings support this hypothesis. The study suggests that colon cancer cells expressing VEGF and its receptor (VEGFR-2) may possess an autocrine growth pathway that can be effectively targeted using RNA interference as an antiangiogenic therapy.

Key Takeaways:

• The study used siRNA to knock down VEGF expression in RKO colon cancer cells, resulting in a 94% decrease in VEGF expression and a 67% decrease in cellular proliferation.
• The RKO cells expressed both VEGF and VEGFR-2, suggesting the presence of an autocrine growth pathway.
• The study found that VEGF inhibition impeded the proliferation of colon cancer cells, providing evidence for the potential use of antiangiogenic therapy in treating colon cancer.
• The researchers demonstrated the effectiveness of siRNA in knocking down VEGF expression in colon cancer cells.
• The results suggest that targeting the VEGF-VEGFR-2 pathway using RNA interference may be an effective strategy for treating colon cancer.
• A.L. Mulkeen and colleagues conducted the study at Yale University, publishing their findings in Archives of Surgery.

Statistics:

• 94% decrease in VEGF expression in RKO cells after siRNA treatment
• 67% decrease in cellular proliferation in RKO cells after siRNA treatment
• The study used real-time quantitative polymerase chain reaction to establish the ability of siRNA to decrease VEGF production.

Sources:

• Mulkeen, A.L., et al. Arch Surg, 2006;141(4):367-374)
• American Medical Association, 515 N State St., Chicago, IL 60610-0946, USA (publisher's contact information)